P3‐018: An Evaluation of the Safety of Nelotanserin, A Highly Potent and Selective 5‐HT2A Inverse Agonist That is Being Developed as a Treatment for Visual Hallucinations and REM Behavior Disorder in Lewy Body Dementia

Saved in:
Bibliographic Details
Published inAlzheimer's & dementia Vol. 12; no. 7S_Part_17; p. P824
Main Authors Wen, Warren, Ramaswamy, Shankar, Piscitelli, Stephen C., Cicero, Sherri, Lynch, Shau Yu, Friedhoff, Lawrence
Format Journal Article
LanguageEnglish
Published The Alzheimer's Association 01.07.2016
Online AccessGet full text

Cover

More Information
ISSN:1552-5260
1552-5279
DOI:10.1016/j.jalz.2016.06.1675